WebFounded. 2024. TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. WebTScan Therapeutics, Inc. (NASDAQ:TCRX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...
TCRX Stock Price and Chart — NASDAQ:TCRX — TradingView
WebIPO Boutique expressly disclaims all warranties of any kind, express or implied, including without limitation any warranty of merchantability or fitness for a particular purpose. Use of our website or publications is provided on an "as is" basis. IPO Boutique content is not to be shared, exchanged or sold to any party or entity. WebApr 13, 2024 · Get a real-time TScan Therapeutics, Inc. (TCRX) stock price quote with breaking news, financials, statistics, charts and more. ... IPO Date Jul 16, 2024. … dyoster caps 0 5+0 4
TSCAN THERAPEUTICS, INC. : Change in Directors or Principal …
WebJul 16, 2024 · TScan Therapeutics, a preclinical biotech developing engineered T cell cancer therapies, raised $100 million by offering 6.7 million shares at $15, the low end of the … WebMar 20, 2024 · Asset Growth. 5.84%. Trailing 12-Months. The TScan Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating … WebHe also developed the T-Scan platform for high-throughput mapping of T cell epitopes and co-founded TScan Therapeutics, ... where he successfully led the company’s 2011 IPO and subsequent debt and equity financings. Prior to Pacira, Jim served as CFO of Bioenvision and Merrimack Pharmaceuticals. dyoshihara defense assessments and analysis